Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2007-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-06-0631PMID 17513604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p53 ubiquitination: Mdm2 and beyond.

  2006cited by this paper
• Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

  2006cited by this paper
• Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus

  2005cited by this paper
• Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2

  2005cited by this paper
• Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K

  2005cited by this paper
• Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy.

  2004cited by this paper
• A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin

  2004cited by this paper
• Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53

  2004influential reference
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• Targeting the p53–MDM2 interaction to treat cancer

  2004cited by this paper
• Regulation of p53 Stability and Function in HCT116 Colon Cancer Cells*

  2004cited by this paper
• Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus AdΔ24-p53 against Human Malignant Glioma

  2004cited by this paper
• p53 from pathway to therapy

  2004cited by this paper
• Replicative Oncolytic Adenoviruses in Multimodal Cancer Regimens

  2003cited by this paper
• Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

  2003cited by this paper
• Therapeutic exploitation of the p53 pathway.

  2002cited by this paper
• Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.

  2002cited by this paper
• Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors

  2002cited by this paper
• Late Expression of p53 from a Replicating Adenovirus Improves Tumor Cell Killing and Is More Tumor Cell Specific than Expression of the Adenoviral Death Protein

  2002cited by this paper
• Live or let die: the cell's response to p53

  2002cited by this paper
• HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.

  2001cited by this paper
• A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo

  2000cited by this paper
• Death Signal-induced Localization of p53 Protein to Mitochondria

  2000cited by this paper
• Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb

  1999cited by this paper
• The MDM2 gene amplification database.

  1998cited by this paper
• p53-dependent cell death/apoptosis is required for a productive adenovirus infection

  1998cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• Implications of the p53 tumor-suppressor gene in clinical oncology.

  1995cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper

• Development and in vivo biodistribution of folate-targeted nanolipid system for erlotinib in breast cancer treatment.

  2025cites this paper
• Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

  2022influential citation
• Evaluation of a Novel Oncolytic Adenovirus Silencing SYVN1

  2022cites this paper
• Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer

  2021cites this paper
• Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity

  2020cites this paper
• Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens

  2018cites this paper
• Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells

  2017cites this paper
• The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

  2016cites this paper
• p53 Replacement Therapy for Cancer.

  2016cites this paper
• Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells

  2015cites this paper
• Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy

  2014cites this paper
• Small molecule compounds targeting the p53 pathway: are we finally making progress?

  2014cites this paper
• Inorganic phosphate as a signaling molecule: a potential strategy in osteosarcoma treatment.

  2013cites this paper
• Advances in adenovirus-mediated p53 cancer gene therapy

  2013cites this paper
• QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants

  2013cites this paper
• Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.

  2013cites this paper
• Mechanisms of therapy resistance in osteosarcoma: a review

  2013cites this paper
• Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53‐dependent pathway

  2013cites this paper
• Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin

  2012cites this paper
• Androgen receptor molecular biology and potential targets in prostate cancer

  2010cites this paper
• p53-based anti-cancer therapies: An empty promise?

  2010cites this paper
• Targeting p53 for enhanced radio- and chemo-sensitivity

  2009cites this paper
• Armed replicating adenoviruses for cancer virotherapy

  2009cites this paper
• Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

  2009cites this paper
• Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins

  2009cites this paper
• Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome

  2009cites this paper
• Etudes moléculaires et fonctionnelles des gènes TSAP6 et TCTP

  2008cites this paper
• PTEN mutation: many birds with one stone in tumorigenesis.

  2008cites this paper
• Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma

  2008cites this paper
• Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

  2008cites this paper
• Chromosome instability and tumor lethality suppression in carcinogenesis

  2008cites this paper
• Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers

  2008cites this paper
• Structural biology of the tumor suppressor p53.

  2008cites this paper